Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report by Pellitteri, Gaia et al.
C A S E  R E P O RT
Orgasmolepsy in Narcolepsy Type 1 Responsive 
to Pitolisant: A Case Report
This article was published in the following Dove Press journal: 
Nature and Science of Sleep




1Clinical Neurology Unit, Department of 
Neurosciences, Udine University 
Hospital, Udine, Italy; 2Department of 
Medicine (DAME), University of Udine, 
Udine, Italy; 3Department of 
Mathematics, Informatics and Physics 
(DMIF), University of Udine, Udine, Italy 
Abstract: We describe a case of a young male patient with narcolepsy type 1 (NT1), who 
developed generalized cataplexy attacks during sexual intercourses, on which we have 
obtained a satisfactory control with pitolisant. Orgasmolepsy is an uncommon feature of 
NT1 that has been poorly described in the literature. The prevalence of this condition is 
unclear, as it is reasonably underreported by patients for embarrassment and not well 
investigated by physicians. Pitolisant is a novel treatment for narcolepsy, effective on 
excessive daytime sleepiness and cataplexy by modulating the histaminergic system. Real- 
world data collection on pitolisant efficacy and safety is still ongoing. However, pitolisant 
effectiveness on orgasmolepsy in NT1 has no precedent in the literature. Orgasmolepsy and 
other sexual disturbances should be actively searched in narcoleptic patients and, if present, 
may guide clinicians to prefer pitolisant or sodium oxybate, avoiding antidepressants for 
their possible sexual side effects. 
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Introduction
Narcolepsy is a chronic, disabling sleep-wake disorder characterized by excessive 
daytime sleepiness (EDS), cataplexy, hypnagogic-hypnopompic hallucinations, 
sleep paralysis, impaired nocturnal sleep and automatic behaviors. These features 
may be differently combined in narcolepsy type 1 (NT1, with cataplexy) and type 2 
(NT2, without cataplexy), with high variability in the clinical presentation of the 
disease.1,2 Often unrecognized and diagnosed late, narcolepsy is a rare disorder 
with an estimated prevalence of 20–50/100.000.3
The diagnosis of NT1 is suspected on the basis of patient medical history and 
confirmed by night polysomnography (PSG) followed by multiple sleep latency test 
(MSLT) and/or hypocretin-1 deficiency (≤110 pg/mL) in the cerebrospinal fluid 
(CSF). Additionally, the human leukocyte antigen (HLA) class II HLA- 
DQB1*0602 allele is found in the 98% of patients with NT1.1,2
Modafinil, armodafinil and solriamfetol are first-line treatments for EDS. 
Sodium oxybate is effective on EDS, cataplexy and fragmented nocturnal sleep, 
while antidepressants are primarily used for cataplexy.2 Pitolisant is a histamine H3 
receptor antagonist/inverse agonist, approved in 2016 by the European Medicines 
Agency (EMA) as a first-line treatment for both EDS and cataplexy. In 2019, it has 
received the approval of the US Food and Drug Administration (FDA) for the 
treatment of EDS in narcolepsy, while the indication for cataplexy is currently 
under review.2,4
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The loss of orexin neurons in the lateral hypothalamus, 
probably mediated by autoimmune mechanisms, plays a key 
role in the pathophysiology of NT1.2 Hypocretin is actively 
involved in the regulation of the dopaminergic system, 
which is crucial for motor control, but also in promoting 
wakefulness, in sexual behavior and reward mechanism.2,5 
Hypocretin deficiency facilitates the transient emotion- 
triggered muscle atonia of cataplexy, due to dysfunctional 
hypothalamus-amygdala-brainstem interactions.4,6
Several sexual disorders may be associated with narco-
lepsy. Hypnagogic hallucinations may present as complex and 
multi-modal experiences with sexual content, which may 
occur at night and during daytime sleepiness moments. 
Hallucinatory episodes of sexual activity combined with out- 
of-body experiences, sexual assaults and extramarital affairs 
leading to social and legal conflicts have been described.7,8 In 
such cases, a comprehensive clinical evaluation is recom-
mended to distinguish between narcolepsy and psychosis. In 
addition, cataplexy in NT1 may occur during sexual inter-
courses facilitated by the emotional trigger. This phenomenon 
was defined “orgasmolepsy” by Jakob Rothfeld, who 
described it for the first time in 1928.9 This embarrassing 
sexual feature of narcolepsy may significantly impact on 
patient’s relational and affective life. However, it is so far 
poorly characterized, as it has been infrequently reported in 
the literature.
Case Report
A 26-year-old man developed EDS and partial cataplexy 
attacks at the age of 13. He arrived to our Sleep Medicine 
Center (Clinical Neurology Unit, Udine University Hospital, 
Italy) at the age of 15, by presenting irrepressible need to 
sleep with an Epworth Sleepiness Scale (ESS) score of 14, 
and sporadic partial cataplexy attacks with sagging of facial 
muscles and head drooping triggered by emotions, lasting 
a few seconds. Tested with night PSG, the patient showed 
a sleep latency of 6.0 minutes with a Rapid Eye Movement 
(REM) sleep latency of 1.0 minute. The MSLT revealed 
a mean sleep latency of 3.2 minutes and Sleep Onset 
Rapid Eye Movement Periods (SOREMPs) in five tests out 
of five (Figure 1). Since diagnostic criteria for NT1 were 
fulfilled, CSF hypocretin level was not assessed. 
Furthermore, he tested positive for HLA-DQB1*0602. The 
patient was initially treated with modafinil 200 mg/day, 
titrated up to 300 mg at the age of 19, with satisfactory 
control on EDS, and ESS scores persistently under 10 at 
follow-up. An add-on treatment with venlafaxine for cata-
plexy was initially considered, but eventually discarded due 
to the poor clinical relevance of cataplectic manifestations.
At the age of 23, the patient reported a major impair-
ment in daytime sleepiness related to a higher workload, 
with an ESS score of 15. At the same time, he also started 
to have cataplexy attacks during sexual intercourses, 
which had previously occurred normally. Muscle atonia 
was generalized, lasting 8–10 seconds in proximity of 
climax, being more intense during the first orgasm in 
case of multiple orgasms within the same intercourse. He 
initially avoided mentioning this problem throughout the 
follow-up visits. Given the worsening of EDS, however, 
we introduced pitolisant 4.5 mg/day as an add-on treat-
ment with modafinil. It was titrated up to 18 mg/day in 
four weeks, obtaining a moderate reduction of EDS (ESS 
Figure 1 Patient hypnogram, night PSG and MSLT findings at the time of diagnosis. 
Abbreviations: PSG, polysomnography; MSLT, multiple sleep latency test; REM, rapid eye movement; SOREMPs, sleep-onset REM periods; W, wakefulness; N1, NREM1 
stage; N2, NREM2 stage; N3, NREM3 stage; R, REM stage; min, minutes.
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score 12) and the resolution of partial cataplexy attacks. 
He continued to increase the dosage by 4.5 mg weekly. At 
a dose of 27 mg/day, he noticed a significant improvement 
of generalized cataplexy during sexual activity and, for the 
first time, he informed us of his sexual disturbance. 
Although orgasmolepsy was still occurring within each 
intercourse, muscle atonia became milder, sparing the 
lower limbs and lasting 2–3 seconds.
At that dosage, however, the patient developed three 
attacks of migraine with aura in two weeks, each one 
occurring 1.5–2 hours after pitolisant intake. Following 
these episodes, he informed us about his personal and 
familial medical history of migraine; he had previously 
experienced rare attacks of aura without migraine, and his 
mother is affected by migraine with aura as well. Pitolisant 
reduction to 18 mg/day prevented other migraine attacks, 
but led to an unsatisfactory control of orgasmolepsy again.
Discussion
Cataplexy triggered by emotions during sexual inter-
courses, formerly known as orgasmolepsy, is a rare man-
ifestation of cataplexy in NT1 that has received poor 
attention in the literature. Aside from a few reports,10,11 
a case series by Poryazova et al is the only study published 
in the last two decades evaluating features and prevalence 
of orgasmolepsy in NT1.5 As observed in our patient, 
orgasmolepsy typically occurs at each sexual intercourse. 
Muscle atonia is often generalized in body distribution and 
more pronounced in case of emotional involvement. 
Poryazova et al described only three patients with orgas-
molepsy in a series of 29 with NT1. Two of them were 
effectively treated for cataplexy with sodium oxybate, but 
orgasmolepsy improved only in one case.5 Differently, our 
patient was effectively treated with pitolisant.
A few clarifications on the relationship between sexual 
disorders and drugs used for narcolepsy should be made. 
Firstly, increased and decreased libido are both reported as 
uncommon adverse events of pitolisant;12 decreased libido is 
also an uncommon side effect of modafinil.13 Secondly, all 
antidepressants used to treat cataplexy in patients with NT1 
are known to be associated with decreased libido, erectile 
dysfunction, delayed orgasm or anorgasmia and delayed 
ejaculation.14 Moreover, cataplexy, which has been described 
as an adverse reaction to modafinil in a patient without 
narcolepsy,15 has also been reported as an uncommon side 
effect of pitolisant.12 In our case, the patient has never 
reported changes in his sexual drive; partial cataplexy was 
already present when he started the treatment with modafinil 
and it remained unchanged for several years; orgasmolepsy 
appeared at a time of global worsening of the disease; finally, 
he clearly showed a dose-related response on both partial 
cataplexy and orgasmolepsy with pitolisant.
Pitolisant is an H3 receptor antagonist/inverse agonist 
effective on EDS and cataplexy.4,16 H3 receptors are highly 
expressed in the amygdala, a region strongly involved in 
cataplexy induction. The amygdala is modulated by hista-
minergic neurons of the tuberomammillary nucleus, which 
are almost doubled in NT1, probably in response to the loss 
of orexin neurons.4,16 It has been hypothesized that orgas-
molepsy may be associated with persisting amygdala firing 
during intercourses and resultant disinhibition of brainstem 
atonia-generating neurons.5 Pitolisant effectiveness on cata-
plexy and orgasmolepsy, therefore, may be related to the 
stimulation of histaminergic neurons in the tuberomammil-
lary nucleus, with consequent amygdala inhibition.
According to the limited data available in the literature, 
prevalence of orgasmolepsy varies between 10% and 31% 
of NT1 patients,5 although it would be expected to be 
more frequent, considering the strong emotional content 
of sexual intercourse. Several explanations are possible for 
this discrepancy: sexual dysfunction could be unreported 
for embarrassment (our patient reported his disturbance 
only after it was improved by pitolisant); given the age 
of onset of narcolepsy, active sexual life may start when 
effective treatments for cataplexy are already ongoing, 
preventing orgasmolepsy. Finally, orgasmolepsy might be 
concealed by other sexual disorders, which frequently 
occur among NT1 patients as part of a dysautonomic 
syndrome, particularly erectile dysfunction in 48% of 
men and vaginal dryness in 81% of women.17
We emphasize the importance of actively searching for 
sexual disturbances in patients with narcolepsy, because 
these represent limiting factors in their relational life. As 
we reported above, sexual disorders may be related to 
medications used for narcolepsy or to the disease itself, 
as in the case of orgasmolepsy. Such information may help 
to clarify data on prevalence and features of this condition 
and should guide clinicians in the choice of an appropriate 
treatment for cataplexy in NT1. We suggest to prefer 
pitolisant or sodium oxybate in narcoleptic patients with 
orgasmolepsy or other sexual disorders, particularly avoid-
ing antidepressants for their common sexual side effects.
Ethical Standard Statement
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